Hot Products
Hot products from BioCrick which is a professional high-purity natural products manufacturer are well known to scientists around the world because of their high purity and stability. Each product is a chemical compound or substance produced by a living organism—that is, found in nature. In the broadest sense, natural products include any substance produced by life.Natural products remain the best sources of drugs and drug leads, and this remains true today despite the fact that many pharmaceutical companies have deemphasized natural products research in favor of HTP screening of combinatorial libraries during the past 2 decades. From 1940s to date, 131 (74.8%) out of 175 small molecule anticancer drugs are natural product-based/inspired, with 85 (48.6%) being either natural products or derived therefrom. From 1981 to date, 79 (80%) out of 99 small molecule anticancer drugs are natural product-based/inspired, with 53 (53%) being either natural products or derived therefrom. Among the 20 approved small molecule New Chemical Entities (NCEs) in 2010, a half of them are natural products.
Hot products from the professional high-purity natural products manufacturer
| Cat.No. | Product Name |
|---|---|
| BCC7168 | ALX 5407 hydrochloride |
| Selective non-transportable inhibitor of the glycine transporter GlyT1 (IC50 values are 3 nM and > 100 μM for human GlyT1c and GlyT2 respectively). Does not recognize other glycine sites, including the glycine site on the NMDA receptor (IC50 > 100 μM). | |
| BCC7172 | UBP 301 |
| Potent kainate receptor antagonist (apparent Kd = 5.94 μM). Displays ~ 30-fold selectivity over AMPA receptors. | |
| BCC7173 | Zimelidine dihydrochloride |
| 5-HT re-uptake inhibitor; selective over noradrenalin and dopamine uptake (IC50 values are 0.33, 8.2 and 12 μM respectively). Modulates nociception and induces hyperglycemia in vivo, and is an orally active antidepressant. | |
| BCC7175 | Ro 106-9920 |
| Inhibitor of NF-κB activation, possibly via selective inhibition of LPS- and TNF-α-induced IκBα ubiquitination (IC50 = 3 μM). Blocks subsequent production of TNF-α, IL-1β and IL-6. Inhibits mucin production in an in vitro model of COPD, and is anti-inflammatory following oral administration in vivo. Also weakly inhibits EGFR, 5-lipoxygenase and iNOS. | |
| BCC7183 | Altanserin hydrochloride |
| Potent and selective 5-HT2A receptor antagonist (Ki values are 0.13, 4.55, 40, 62 and 1570 nM at 5-HT2A, α1, 5-HT2C, D2 and 5-HT1A respectively). Centrally active following systemic administration in vivo. | |
| BCC7185 | Indirubin-3'-oxime |
| Protein kinase inhibitor; inhibits cyclin-dependent kinases (IC50 = 0.18 - 3.33 μM) and GSK-3β (IC50 = 0.19 μM). Inhibits CDK5- and GSK-3β-mediated tau phosphorylation, a process over-active in Alzheimer disease states. Also inhibits AMPK, LCK and SGK. Induces cell cycle arrest and inhibits cell proliferation. | |
| BCC7187 | Palmitoylisopropylamide |
| Inhibitor of fatty acid amide hydrolase (FAAH); pIC50 = 4.89 for inhibition of [3H]-anandamide metabolism. Displays little binding to CB1 and CB2 receptors (IC50 > 100 μM) and very weakly blocks anandamide uptake (IC50 ~ 100 μM). Inhibits proliferation of C6 glioma cells. | |
| BCC7189 | Demethylasterriquinone B1 |
| Selective insulin receptor (IR) activator (EC50 values are 3 - 6 μM for IRTK and 100 μM for IGF1R and EGFR). Increases IR β subunit tyrosine phosphorylation and activation of PI 3-kinase and Akt, but not ERK. Induces glucose uptake in adipocytes and skeletal muscle in vitro, without enhancing vascular proliferation. Binds GAPDH. Also activates Trk by interacting at a site distinct from the neurotrophin-binding site. | |
